

1 **Age-Dependent Expression of 5 α -Reductase and Androgen Receptors mRNA by the**
2 **Canine Prostate**

3 **F. Shidaifat**

4

5 *Department of Basic Veterinary Medical Sciences, Faculty of Veterinary Medicine,*

6 *Jordan University of Science and Technology, Irbid 22110, Jordan*

7 **Summary**

8

9 The growth of the prostate gland is androgen-dependent in which testosterone is
10 converted to the most potent dihydrotestosterone (DHT) by 5 α -reductase within the
11 prostate. Androgen interacts with its androgen receptors (AR) to regulate normal growth
12 of the prostate and has been also implicated in both the progression of benign prostate
13 hyperplasia and prostate cancer. This study was conducted to compare the mRNA
14 expression of AR and 5 α -reductase by the prostate gland from three age categories:
15 immature, young-mature and old dogs. Quantitative gene expression was assessed by the
16 real-time PCR and the results were expressed as a relative mRNA expression of the target
17 gene. This study revealed that there was no significant ($P > 0.05$) difference in the mRNA
18 expression of the AR by the prostate gland of immature, young and old dogs. In contrast
19 to mRNA expression of AR gene, there is a highly significant ($P < 0.001$) down-regulation
20 in 5 α -reductase gene by the prostate of young and old dogs as compared with immature
21 dogs. However, there is no significant ($P > 0.05$) difference in mRNA expression of the
22 5 α -reductase gene by the prostate gland from young and old dogs. This differential
23 expression of AR and 5 α -reductase genes, which are involved in the regulation of
24 androgen effect on prostate gland, might reflect an age-dependent growth requirement of
25 the gland for androgens.

26 Key words

27 Prostate, androgen receptors, 5 α -reductase, canine

28

29 Continuous supply of androgen is a prerequisite for driving the prostate gland growth and
30 for maintaining its steady-state growth. Androgen has also been implicated in the
31 progression of prostatic diseases, such as benign prostate hyperplasia (BPH) and prostate
32 cancer. Although testosterone is the prevalent circulating androgen, dihydrotestosterone
33 (DHT) is the most active androgen involved in the regulation of the prostate gland. The
34 conversion of testosterone to its active metabolite is achieved through the activity of 5 α -
35 reductase, which occurs in two isozymes, type I and type II. While the type II
36 predominantly is expressed by prostatic cells, type I is expressed by other tissues, such as
37 skin and liver. Deficiency of type II but not type I severely impeded the prostate gland
38 development in human and to a lesser extent in rats (Imperato-Mcginley and Zhu 2002,
39 Carson and Rittmaster 2003, Mahendroo *et al.* 2001). Therefore, inhibitors of 5 α -
40 reductase, which were adapted as therapeutic agents for the treatment of BPH, resulted in a
41 significant reduction in the prostate gland size (Tarter and Vaughan 2006, Cohen *et al.*
42 1995, Laroque *et al.* 1995).

43

44 Androgen exerts its effect on prostate gland development through the interaction with
45 androgen receptor (AR). AR acts as a transcription factor that regulates the expression of
46 androgen response genes that are involved in many cellular activities that ranges from
47 proliferation to programmed cell death (So *et al.* 2003). AR expression level has been
48 shown to increase in close association with the continuous growth of the dorsal and
49 lateral lobes of the prostate gland in some rat strains which develop an age-dependent
50 spontaneous hyperplasia (Banerjee *et al.* 2001). In contrast, AR expression level has
51 been shown to decrease in the ventral lobe of the gland, which exhibited age-dependent

52 growth senescence (Banerjee *et al.* 2001). Androgen ablation studies also revealed in rats
53 a rapid regression of the ventral lobe of the prostate gland by inducing epithelial cell
54 apoptosis (Perlman *et al.* 1999, Banerjee *et al.* 2000, Banerjee *et al.* 2002) but not in the
55 dorsolateral lobes (Banerjee *et al.* 2002). In addition, AR expression has been shown to
56 be associated with cell proliferation and survival of prostate cancer and it might therefore,
57 contribute to prostate cancer progression (Amirghofran *et al.* 2004). These results
58 demonstrate clearly the importance of androgen receptor expression level in regulating
59 the rates of prostate gland growth and senescence.

60

61 Dogs are known to develop an age-dependent spontaneous prostate hyperplasia (Brendler
62 *et al.* 1983). Although this process is androgen-dependent, the expression of genes that
63 are involved in the regulation of androgen action, such as AR receptor and 5 α -reductase,
64 are not well established. Therefore, this study was designed to compare the mRNA
65 expression levels of AR and 5 α -reductase (Type II) genes by the prostate gland in
66 immature, young and aged dogs.

67

68 To conduct this experiment, twelve male dogs were divided into three age groups:
69 immature, young-adult and old-adult dogs. Each group had 4 dogs. The immature dogs
70 were about 1 month of age, the young dogs were about two years old, and the old dogs
71 were between 6-8 years of age. After the dogs were euthanized by intravenous injection
72 of 10% thiopentone sodium, the prostate glands were removed and stored in liquid
73 nitrogen for subsequent RT-PCR analysis. The protocol of animal handling and

74 euthanasia were approved by the Jordan University of Science and Technology Animal
75 Care and Use Committee (JUST-ACUC).

76

77 Total RNA was extracted from the frozen prostate gland using an SV Total RNA
78 isolation kit (Promega Corporation, Madison, WI, USA). The RNA concentration was
79 determined by measuring the absorbance at 260 nm using SmartSpec™ Plus
80 spectrophotometer (Bio-Rad, Hercules, CA, USA). 0.5 µg of total RNA was used to
81 synthesize a complementary DNA (cDNA) using the reverse transcription kit (Promega
82 Corporation, Madison, WI, USA). The RT reaction was carried out at 25 °C for 5 min
83 followed by 42 °C for 60 min and then at 95 °C for 5 min. The samples were then placed
84 on ice for 5 minutes and stored at -20 °C for PCR amplification.

85

86 Real time PCR analysis was performed using a commercial PCR kit containing
87 sybergreen florescent dye (QuantiTect™ SYBR® Green; Qiagen, Valencia, CA, USA) in
88 the presence of 2 µM of specific primers. The primers were designed to be specific for
89 the canine sequence using the web-based QuantiProb Design software (QuantiTec
90 Cuatom Assays, www.qiagen.com). The forward sequence for the primer used for
91 androgen receptors was GAG GTA GTA TCA GAA GGT AG and the reverse primer
92 was CTG TCC GAG ATG GTC GAA. The forward primer for 5α-reductase type II was
93 ACT CAT TGC TCA CTA GAG G and the reverse primer was CTC AGC GCA GTA
94 AAT CAG A. The forward sequence for glyceraldehyde-3-phosphate dehydrogenase
95 (GAPDH) primer was CTG GAG AAA GCC AAA and the reverse primer was TGT
96 TGA CAC AGG AGA. The PCR amplification reactions were started with an initial

97 denaturation at 95 °C for 15 min, followed by 45 cycles each composed of denaturation at
98 95 °C for 30 sec, annealing at 55 °C for 30 sec and extension at 72 °C for 30 sec. At the
99 end of the 45 cycles the melting curve for the reactions was performed at temperatures
100 ranging from 72°C to 95°C.

101

102 Relative mRNA gene expression was determined using the $2^{-\Delta\Delta C_T}$ method and
103 normalized to GAPDH expression (Livak and Schmittgen, 2001). One-way analysis of
104 variance (ANOVA) of mRNA expression was performed using Minitab software
105 (Minitab Inc., State College, PA, USA). The results were presented as the mean \pm SEM.
106 A probability of less than 0.05 ($P < 0.05$) was considered statistically significant. The
107 mRNA expression of each gene was twice analyzed from different pools of total RNA.

108

109 The results of this study revealed a differential mRNA expression of AR and 5 α -
110 reductase type II genes by the prostate gland obtained from immature, young and old
111 dogs. As shown in figure 1, there is a highly ($P < 0.001$) significant reduction in 5 α -
112 reductase mRNA expression by the prostate gland from young and old dogs as compared
113 with its expression in prostates of immature dogs. However, there is no significant
114 difference in 5 α -reductase mRNA expression between young and old prostate glands. It
115 has been shown that inhibition of 5 α -reductase resulted in a significant decrease in
116 prostate gland volume probably by inducing prostatic cell apoptosis (Laroque *et al.* 1995,
117 Steers 2001). This reduction in the prostate gland size correlated well with a decrease in
118 DHT and the concomitant increase in testosterone level (Cohen *et al.* 1995), indicating
119 that DHT rather than testosterone play a key permissive role in the prostate gland growth

120 and development. It has been shown that the physiological concentration of testosterone
121 is higher in adults as compared to immature_dogs (Brendler *et al.* 1983, Mialot *et al.*
122 1988). Therefore, the present results emphasized the importance of 5 α -reductase as a rate
123 limiting step for the reduction of the effective concentration of testosterone within the
124 prostate gland in young- and old-adult dogs and thus should reduce the prostate gland
125 growth. Surprisingly, the canine prostate gland continued its post-maturation growth
126 (Brendler *et al.* 1983) despite this highly significant inhibition of 5 α -reductase. One
127 possible explanation for this discrepancy might be due to the fact that DHT is an
128 immediate precursor for 3 β Adiol which interact with estrogen receptor β (ER β) and acts
129 as a negative regulator of prostate gland growth. Therefore, the inhibition of 5 α -
130 reductase would also prevent the formation of 3 β Adiol and, by doing so, would remove
131 the growth-limiting effect of ER β (Weihua *et al.* 2002).

132

133 In contrast to the expression of 5 α -reductase, there is no significant difference in AR
134 mRNA expression by prostate gland of immature, young and old dogs (Figure 2).
135 Androgen receptor expression has been shown to vary in an age- and species-dependent
136 manner. Although AR expression by the ventral lobes of rats prostate shows an age-
137 dependent decrease (Banerjee *et al.* 2001, Prins *et al.* 1996), its expression level by young
138 adult and old dogs remained either unchanged (Prins *et al.* 1996) or increased with age
139 (Niu *et al.* 2003). This age-dependent and species-specific variation in AR receptor
140 expression appeared to parallel the inherent differential character of age-dependent
141 growth and senescence of the prostates in rat and dogs. While the rat prostate gland
142 growth ceases after maturity, the dog prostate continues to grow as the animal gets older.

143 However, in some rat strains when there is a tendency of the dorsal and lateral lobes of
144 the rat prostate gland to continue its development beyond the mature state, there is a
145 parallel increase in AR expression (Banerjee *et al.* 2001). Interestingly, the spontaneous
146 and age-dependent development of prostate hyperplasia has been shown to occur despite
147 the decrease of serum testosterone level (Banerjee *et al.* 1998). Therefore, the increment
148 of AR expression might act to enhance the responsiveness of prostatic cells to androgen
149 stimulation and to compensate for its decline. As the dogs are known to develop an age-
150 dependent benign prostate hyperplasia, then the consistent expression level of AR by the
151 dog prostate gland from different ages, might be at least in part, involved in its
152 continuous growth.

153

154 In conclusion, the results presented herein demonstrated that the expression level of AR
155 is consistent with the expected age-dependent continuous growth of the prostate gland.
156 The transition of the prostate gland from immature to mature required a dramatic down-
157 regulation in 5 α -reductase expression; nevertheless, a steady-state of its expression is
158 required for the post-maturation growth.

159

160 **Acknowledgments**

161 This study was supported by the Jordan University of Science and Technology and the
162 World Bank project for higher education development

163

164 **References**

165 AMIRGHOFRAN Z, MONABATI A, GHOLIJANI N: Androgen receptor expression
166 in relation to apoptosis and expression of cell cycle related protein in prostate
167 cancer. *Pathol Oncol Res* **10**: 37-41, 2004.

168 BANERJEE PP, BANERJEE S, BROWN TR: Increased androgen receptor
169 expression correlates with development of age-dependent, lobe-specific
170 spontaneous hyperplasia of Brown Norway rat prostate. *Endocrinology* **142**:
171 4066-4075, 2001.

172 BANERJEE PP, BANERJEE S, BROWN TR: Bcl-2 protein expression correlates
173 with cell survival and androgen independence in rat prostatic lobes.
174 *Endocrinology* **143**: 1825-1832, 2002.

175 BANERJEE S, BANERJEE PP, BROWN TR: Castration-induced apoptotic cell death in
176 the brown Norway rat prostate decreases as function of age. *Endocrinology* **142**:
177 821-832, 2000.

178 BANERJEE PP, BANERJEE S, LAI JM, STRANDBERG JD, ZIRKIN BR,
179 BROWN TR: Age-dependent and lobe-specific spontaneous hyperplasia in
180 the brown Norway rat prostate. *Biol Reprod* **59**: 1163-1170, 1998.

181 BRENDLER CB, BERRY SJ, EWING LL, MCCULLOUGH AR, COCHRAN RC,
182 STRANDBERG JD, ZIRKIN BR, COFFEY DS, WHEATON LG, HILER
183 ML, BORDY MJ, NISWENDER GD, SCOTT WW, WALSH PC:
184 Spontaneous benign prostatic hyperplasia in the beagle. Age-associated
185 changes in serum hormone levels, and the morphology and secretory function
186 of the canine prostate. *J Clin Invest* **71**: 1114-1123, 1983.

187 CARSON C, RITTMASER R: The role of dihydrotestosterone in benign prostatic
188 hyperplasia. *Urology* **61** (suppl 4A): 2-7 2003.

189 COHEN S M, WERRMANN JG, RASMUSSEN GH, TANAKA WK, MALATESTA
190 PF, PRAHALADA S, JACOBS JG, HARRIS G, NETT TM: Comparison of the
191 effect of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine
192 hyperplastic prostate: suppression of prostatic DHT correlated with prostate
193 regression. *Prostate* **26**: 55-71, 1995.

194 IMPERATO-MCGINLEY J, ZHU Y-S: Androgen and male physiology the
195 syndrome of 5 α -reductase-2 deficiency. *Mol Cell Endocrinol* **98**: 51-59, 2002.

196 LAROQUE PA, PRAHALADA S, MOLON-NOBLOT S, COHEN SM, SOPER K,
197 DUPRAT P, PETER CP, VAN ZWIETEN MJ: Quantitative evaluation of
198 glandular and stromal compartment in hyperplastic dog prostate: effect of 5-
199 alpha reductase inhibitors. *Prostate* **27**: 121-128, 1995.

200 LIVAK KJ, SCHMITTGEN TH: Analysis of relative gene expression data
201 using real-time quantitative PCR and the 2^{- $\Delta\Delta$ C_T}. *Methods* **25**: 402-408, 2001.

202 MAHENDROO MS, CALA KM, HESS DL, RUSSELL DW: Unexpected virilization in
203 male mice lacking steroid 5a-reductase enzymes. *Endocrinology* **142**: 4652-4662,
204 2001.

205 MIALOT JP, THIBIER M, TOUBLANC JE, CASTANIER M, SCHOLLER R: Plasma
206 concentration of luteinizing hormone, testosterone, dehydroepiandrosterone,
207 androstenedione between birth and one year in the male dog: longitudinal study
208 and hCG stimulation. *Andrologia* **20**: 145-154, 1988.

209 NIU YJ, MA TX, ZHANG J, XU Y, HAN R.F, SUN G: Androgen and prostatic stroma.
210 *Asian J Androl* **5**: 19-26, 2003.

211 PERLMAN H, ZHANG X, CHEN MW, WALSH K, BUTTYAN R: An elevated
212 bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis.
213 *Cell Death Differ* **6**: 48-54, 1999.

214 PRINS GS, JUNG MH, VELLANOWETH RL, CHATTERJEE B, ROY AK: Age-
215 dependent expression of the androgen receptor gene in the prostate and its
216 implication in glandular differentiation and hyperplasia. *Dev Genet* **18**: 99-106,
217 1996.

218 SO AI, HURTADO-COLL A, GLEAVE ME: Androgen and prostate cancer. *World J*
219 *Urol* **21**: 325-337, 2003.

220 STEERS WD: 5alpha-reductase activity in the prostate. *Urology* **58**: 17-24, 2001.

221 TARTER TH, VAUGHAN EDJR: Inhibitors of 5alpha-reductase in the treatment of
222 benign prostatic hyperplasia. *Curr Pharm Des* **12**: 775-783, 2006.

223 WEIHUA Z, LATHE R, WARNER M, GUSTAFSSON J-A: An endocrine pathway in
224 the prostate, ER β , AR, 5 α -androstane-3 β ,17 β -diol, and CYP7B1, regulates
225 prostate growth. *PNAS* **99**: 13589-13594.

226 **Figure 1:** Relative mRNA expression of 5 α -Reductase type II by the prostate gland from
227 immature, young-adult dogs and old-adult dogs. Each bar represents the mean \pm SEM of
228 4 dogs. Bars with different letters represent means that are significantly different (P<
229 0.001).

230

231 **Figure 2:** Relative mRNA expression of androgen receptor by the prostate gland from
232 immature, young-adult and old-adult dogs. Each bar represents the mean \pm SEM of 4
233 dogs. There were no significant statistical differences between groups (P>0.05).




Figure 1




Figure-2